Blinatumomab is a monoclonal antibody of the BiTE (bispecific T-cell engager) class, engineered through the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV via a short peptide linker. CD3 is an antigen present on T-cell surfaces, while CD19 is predominantly found on malignant B-cells. By binding to both antigens, blinatumomab effectively redirects T-cells towards tumor cells expressing CD19, thereby facilitating tumor cell lysis and apoptosis. Blinatumomab has been particularly noted for its efficacy in treating relapsed or refractory acute lymphoblastic leukemia (ALL), demonstrating significant response rates in clinical trials. Its unique design not only enhances specificity but also minimizes off-target effects, making it a promising candidate in targeted cancer therapies.